
FIVE expands through new stores, value pricing and digital engagement, while M advances its turnaround with Reimagine stores, luxury banners and AI initiatives.
Macy's, Inc., an omnichannel retail organization, operates stores, websites, and mobile apps under the Macy's, Bloomingdale's and bluemercury brands. The company is headquartered in New York, New York.
| Revenue (TTM) | $22.72B |
| Gross Profit (TTM) | $9.16B |
| EBITDA | $1.41B |
| Operating Margin | 1.76% |
| Return on Equity | 14.40% |
| Return on Assets | 3.37% |
| Revenue/Share (TTM) | $85.00 |
| Book Value | $18.39 |
| Price-to-Book | 1.36 |
| Price-to-Sales (TTM) | 0.29 |
| EV/Revenue | 0.457 |
| EV/EBITDA | 5.60 |
| Quarterly Earnings Growth (YoY) | 76.90% |
| Quarterly Revenue Growth (YoY) | 2.10% |
| Shares Outstanding | $263.04M |
| Float | $258.79M |
| % Insiders | 1.52% |
| % Institutions | 98.50% |
Volatility is currently expanding

FIVE expands through new stores, value pricing and digital engagement, while M advances its turnaround with Reimagine stores, luxury banners and AI initiatives.

LONDON / ACCESS Newswire / July 29, 2026 / Ecora (LSE:ECOR)(TSX:ECOR)(OTCQX:ECRAF) issues the following trading update for the period 1 April to 30 June 2026. Marc Bishop Lafleche, Chief Executive Officer of Ecora, commented: "Q2 was a strong quarter, with the producing critical minerals portfolio continuing to demonstrate its cash generation potential.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

M, AMP and OPHC made it to the Zacks Rank #1 (Strong Buy) value stocks list on July 28, 2026.

NXRT, M and CCS made it to the Zacks Rank #1 (Strong Buy) income stocks list on July 28, 2026.

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary H1 2026 % Change Q2 2026 % Change $m Actual CER1 $m Actual CER - Product Sales 28,896 8 5 14,510 5 4 - Alliance Revenue 1,699 31 29 874 34 33 Product Revenue 30,595 9 6 15,384 6 5 Collaboration Revenue 77 (6) (9) - n/m n/m Total Revenue 30,672 9 6 15,384 6 5 Reported EPS ($) 3.60 4 3 1.61 2 (2) Core2 EPS ($) 5.21 12 11 2.63 21 18 Key performance elements for H1 2026 (Growth numbers at constant exchange rates) Total Re.

Macy's is navigating a challenging retail environment with a focus on strategic initiatives and disciplined cost management - which seems to be paying off. Recent sales trends highlight both ongoing headwinds and pockets of resilience within M's core business segments. Consumer confidence remains a critical variable, directly impacting M's near-term revenue trajectory and inventory management.

Investors need to pay close attention to M stock based on the movements in the options market lately.

Macy's (M) reached $23.21 at the closing of the latest trading day, reflecting a +1.89% change compared to its last close.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on M and any ticker you trade — then tracks every position and per-strategy win rate.